Menarini Silicon Biosystems, 3401 Masons Mill Road, Huntingdon Valley, recently made headlines for an in-house study, the results of which represent “an invaluable tool to predict disease aggressiveness and pathology,” researchers say.

In laymen’s terms, the study found that by using Menarini’s patented system and test, health practitioners are better able to monitor and manage patients with Multiple Myeloma.

The study was conducted in collaboration with Dana-Farber Cancer Institute researchers and published on December 7, 2022 in Cancer Discovery, a peer-reviewed medical journal published by the American Association for Cancer Research. 

For extensive coverage on the study’s implications and findings, you can read Yahoo Life’s article here. For more on Manarini Silicon Biosystems, you can visit their website.

Photo credits: Menarini Silicon Biosystems and the CDC